Do fractional doses of pneumococcal conjugate vaccines (PCV10 & PCV13) elicit non-inferior immunogenicity to full doses in Kenyan infants? The preliminary results of ‘the FPCV trial

Description

Regular scientific seminar

Objectives

Presenters

1. Dr. Katherine Gallagner
   Associate professor of epidemiology, KWTRP?LSTMH Since July 2018 I have been based at the KEMRI-Wellcome Trust Research Programme in Kilifi, Kenya, setting up a trial to assess whether lower doses of two of the currently available pneumococcal conjugate vaccines protect Kenyan infants as well as the full dose schedules. We will compare the immune response and carriage of the pneumococcus in the nose (a surrogate marker for disease) after vaccination with a full, 40% or 20% dose schedule. The results could be used to enable countries unable to afford the full cost of the vaccine, to continue delivering it in the childhood immunisation programme in the absence of Gavi support. During the COVID-19 pandemic, I designed a household study of SARS-CoV-2 transmission and ran sero-surveillance among women attending antenatal care in Kenya.
   LSTMH, KWTRP